Dr. Wael M. ElShamy
My Social Links

Dr. Wael M. ElShamy

Associate Professor
San Diego Biomedical Res Institute, California

Highest Degree
Ph.D. in Medical Biochemistry and Biophysics from Karolinska Institutet, Sweden

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Cancer Biology
62%
Neurobiology
90%
Biochemistry
75%
Pathology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Sinha, A., B.T. Paul, L.M. Sullivan, H. Sims and A. El Bastawisy et al., 2017. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget, 8: 10114-10135.
    Direct Link  |  
  2. Ryan, D., A. Sinha, D. Bogan, J. Davies, J. Koziol and W.M. ElShamy, 2017. Correction: A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment. Oncotarget, Vol. 8. .
    Direct Link  |  
  3. Bogan, D., A. Bahnassy, A. El-Bastawisy, H. Yousef, A.R. Zekri and W.M. ElShamy, 2017. Role of BRCA1-IRIS in the development of triple negative breast cancers in Egyptian women: Possible association with TNBC early lesion. BMC Cancer, Vol. 15. 10.1186/s12885-017-3283-8.
    CrossRef  |  
  4. ElShmay, W.M., 2016. The protective effect of longer duration of breastfeeding against pregnancy-associated triple negative breast cancer. Oncotarget, 7: 53941-53950.
    Direct Link  |  
  5. ElShamy, W.M., A. Sinha and N. Said, 2016. Aggressiveness niche: Can it be the foster ground for cancer metastasis precursors? Stem Cells Int., 10.1155/2016/4829106.
    CrossRef  |  Direct Link  |  
  6. ElShamy, W.M., 2016. The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression. Oncoscience, 3: 145-146.
    Direct Link  |  
  7. Ananthula, S., A. Sinha, M. El Gassim, S. Batth and G.D. Marshall et al., 2016. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. Oncotarget, 7: 20869-20889.
    CrossRef  |  Direct Link  |  
  8. Paul, B.T., Z. Blanchard, M. Ridgway and W.M. ElShamy, 2015. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene, 34: 3036-3052.
    CrossRef  |  Direct Link  |  
  9. Blanchard, Z., B.T. Paul, B. Craft and W.M. ElShamy, 2015. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res., Vol. 17. 10.1186/s13058-014-0512-9.
    CrossRef  |  Direct Link  |  
  10. Blanchard, Z., N. Mullins, P. Ellipeddi, J.M. Lage and S. McKinney et al., 2014. Geminin overexpression promotes imatinib sensitive breast cancer: A novel treatment approach for aggressive breast cancers, including a subset of triple negative. Plos One, Vol. 9. 10.1371/journal.pone.0095663.
    CrossRef  |  Direct Link  |  
  11. ElShamy, W.M. and R.J. Duhe, 2013. Overview: Cellular plasticity, cancer stem cells and metastasis. Cancer Lett., 341: 2-8.
  12. Shimizu, Y., N. Mullins, Z. Blanchard and W.M. ElShamy, 2012. BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget, 3: 299-313.
    Direct Link  |  
  13. Shimizu, Y., H. Luk, D. Horio, P. Miron and M. Griswold et al., 2012. BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. PLoS One, Vol. 7. 10.1371/journal.pone.0034102.
    CrossRef  |  Direct Link  |  
  14. Gardner, L., R. Malik, Y. Shimizu, N. Mullins and W.M. ElShamy, 2011. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. Breast Cancer Res., Vol. 13. 10.1186/bcr2884.
    CrossRef  |  Direct Link  |  
  15. Blanchard, Z., R. Malik, N. Mullins, C. Maric and H. Luk et al., 2011. Geminin overexpression induces mammary tumors via suppressing cytokinesis. Oncotarget, 2: 1011-1027.
    Direct Link  |  
  16. Elshamy, WM., 2010. Induction of breast cancer in wild type p53 cells by BRCA1-IRIS overexpression. Hawaii Med. J., 69: 200-201.
  17. Chock, K.L., J.M. Allison, Y. Shimizu and W.M. ElShamy, 2010. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res., 70: 8782-8791.
  18. Chock, K., J.M.S. Allison and W.M. ElShamy, 2010. BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells. Oncogene, 29: 5274-5285.
    CrossRef  |  Direct Link  |  
  19. Pujana, M., J.D. Han, L. Starita, M. Tewari and J. Ahn et al., 2007. A breast cancer network model Establishes a link between BRCA1 and centrosome dysfunction. Nature Genet., 39: 1338-1349.
  20. Hao, L. and W.M. ElShamy, 2007. BRCA1‐IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR. Int. J. Cancer, 121: 39-46.
    Direct Link  |  
  21. Nakuci, E., S. Mahner, J. DiRenzo and W.M. ElShamy, 2006. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp. Cell Res., 312: 3120-3131.
    CrossRef  |  Direct Link  |  
  22. Nakuci, E., M. Xu, M.A. Pujana, J. Valls and W.M. ElShamy, 2006. Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis. Int. J. Biochem. Cell Biol., 38: 1207-1220.
    CrossRef  |  Direct Link  |  
  23. ElShamy, W., 2005. Epithelial to mesenchymal transition, cell surface receptors activation and intracellular communications in cancer metastasis. Cancer Ther., 3: 443-460.
  24. ElShamy, W.M. and D.M. Livingston, 2004. Identification of BRCA1-IRIS, a BRCA1 locus product. Nature Cell Biol., 6: 954-967.
    CrossRef  |  Direct Link  |  
  25. Avni, D., H. Yang, F. Martelli, F. Hofmann and W.M. ElShamy et al., 2003. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol. Cell, 12: 735-746.
    CrossRef  |  Direct Link  |  
  26. ElShamy, W.M., L.K. Fridvall and P. Ernfors, 1998. Growth arrest failure, G1 restriction point override and S phase death of sensory precursor cells in the absence of neurotrophin-3. Neuron, 21: 1003-1015.
    CrossRef  |  Direct Link  |  
  27. Nosrat, C.A., J. Blomlof, W.M. ElShamy, P. Ernfors and L. Olson, 1997. Lingual deficits in BDNF and NT3 mutant mice leading to gustatory and somatosensory disturbances, respectively. Development, 124: 1333-1342.
    Direct Link  |  
  28. Naveilhan, P., W.M. ElShamy and P. Ernfors, 1997. Differential regulation of mRNAs for GDNF and its receptors Ret and GDNFRα after sciatic nerve lesion in the mouse. Eur. J. Neurosci., 9: 1450-1460.
    CrossRef  |  Direct Link  |  
  29. ElShamy, W.M. and P. Ernfors, 1997. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4 complement and cooperate with each other sequentially during visceral neuron development. J. Neurosci., 17: 8667-8675.
    CrossRef  |  Direct Link  |  
  30. Ernfors, P., M.L. Duan, W.M. Elshamy and B. Canlon, 1996. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nature Med., 2: 463-467.
    CrossRef  |  Direct Link  |  
  31. Elshamy, W.M. and P. Ernfors, 1996. Requirement of neurotrophin-3 for the survival of proliferating trigeminal ganglion progenitor cells. Development, 122: 2405-2414.
    Direct Link  |  
  32. ElShamy, W.M., S. Linnarsson, K.F. Lee, R. Jaenisch and P. Ernfors, 1996. Prenatal and postnatal requirements of NT-3 for sympathetic neuroblast survival and innervation of specific targets. Development, 122: 491-500.
    Direct Link  |  
  33. ElShamy, W.M. and P. Ernfors, 1996. A local action of neurotrophin-3 prevents the death of proliferating sensory neuron precursor cells. Neuron, 16: 963-972.
    CrossRef  |  Direct Link  |  
  34. Walum, E., G. Eriksson, A. Peterson, E. Holme, N.G. Larsson, C. Eriksson and W. El‐Shamy, 1995. Use of primary cultures and continuous cell lines to study effects on astrocytic regulatory functions. Clin. Exper. Pharmacol. Physiol., 22: 284-287.
    CrossRef  |  Direct Link  |